Targeting key cardiovascular risk factors for two full years was not linked to a reduced risk of cognitive decline or dementia.

The new approach allows private practices to expand and evolve without being acquired.

The OmniaSecure defibrillation lead from Medtronic is already approved for placement in the right ventricle. This latest approval covers the left bundle branch area, opening the door for conduction system pacing and other advanced techniques.

The COVID-19 pandemic created a major shift in how telehealth services were being utilized. Those services were used much more often for some patient populations than others.

Advanced AI software developed by Cleerly consistently produced plaque assessments comparable to intravascular ultrasound. 

When patients without diabetes land in the hospital after a heart attack or stroke, early treatment with tirzepatide may prove beneficial. 

Bringing in a new and improved cardiovascular IT system can save physicians a ton of time and lead to considerable cost savings.

Novo Nordisk will be selling the new 7.2-mg dose under the brand name Wegovy HD. The FDA's decision fell under a new pilot program intended to grant certain companies improved access and quicker approvals. 

The Cardiovascular Business Forty Under 40 Class of 2026 represents an accomplished group of clinicians, researchers, entrepreneurs and administrators who are redefining what cardiovascular leadership looks like under the age of 40. 

The next-generation valve from Corcym features a sutureless frame as well as laser-cut leaflets and thread holes.